TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: chair sit-and-reach length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Cerebral VMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the dyspnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No serious complications observed during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Remission of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Remission of anxiety
Endpoint domain: Adverse events/effects
Primary endpoint: CSHQ Sleep Onset Delay
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: CSHQ Parasomnias
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: CSHQ Night Wakings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: plasma total GSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rectocele size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of septum to uterus length preoperatively and postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: desire for cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high from cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood to use cocaine if given access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement in patients with poor performance status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart failure death or hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Median pain score during injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of lipid peroxides to nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activity of superoxide dismutase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TKA survival
Endpoint domain: Mortality/survival
Primary endpoint: PLD-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation of spontaneous ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance of telcagepant
Endpoint domain: Adverse events/effects
Primary endpoint: diarrhea period prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean number of days ill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of diarrheal episodes per person per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AAOS (Alcohol-Associated Outcomes Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: γ‐glutamyltransferase blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain severity during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prognosis quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall diagnostic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h cortisol (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: median plasma ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time from termination of anesthesia to recovery of spontaneous breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from termination of anesthetic use to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal increases in the posterior cingulate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive (i.e. psychosis‐like) symptoms induced by ketamine
Endpoint domain: Adverse events/effects
Primary endpoint: Definition of fold pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Translucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of MI type 4a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of time spent < 4.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time spent in target range 4.0-10.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to first hypoglycaemic episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gametocyte density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of postoperative atrial fibrillation (POAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of early menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: plasma lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary urea nitrogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ectasia of central corneal posterior surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to pay (WTP) for multivitamins
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in total costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in MGI (Modified Gingival Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PI (Plaque Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BOP (Bleeding on Probing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Positive and Negative Syndrome Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survey completion rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS score during and 30 min after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramsay score during operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of artificial abortion syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of coughing
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of gagging
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of laryngospasm
Endpoint domain: Adverse events/effects
Primary endpoint: 3-month cumulative incidence of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: occurrence of pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of cancer detection methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete therapeutic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor recurrences during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival without recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Star Excursion Balance Test reach distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐reported instability feeling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Grade 2 and 3 neuropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Ntx-12 questionnaire total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in SCBM per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient-rated severity of constipation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Assessment of Constipation-Quality of Life (PAC-QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: discomfort/pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of slow-wave activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean blood pressure (mBP) pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort and preparedness to discuss spirituality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ability to obtain a patient's spiritual history
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC0-∞ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 (half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sick leave costs
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: mean platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postpartum weight retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of plaque progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose uptake in muscle and adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ETS-induced symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in thigh circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average sodium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants consuming sodium greater than 2,300 mg/d
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants consuming sodium greater than 1,500 mg/d
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PD reduction at deep sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of deep pockets resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF TGF‐beta(1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who completed the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: decreasing behavioral sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreasing cardiovascular sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Homologous hemagglutination inhibition antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of post‐traumatic endophthalmitis
Endpoint domain: Adverse events/effects
Primary endpoint: sexual desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sexual pleasure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gall bladder emptying ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mouth to caecum transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Semen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total sperm count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: cumulative incidence of recurrent peptic ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Grade 3 or 4 nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Complete healing at day 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting Metabolic Rate (SMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of CVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SpHb-tHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (> or = 50% improvement of depression scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission (final depression score < or = 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTPdi/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health-related quality of life information
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: theoretical knowledge acquisition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychiatric relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: practitioner satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of workers identified with NRL allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FNEMG activity during emergence from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient movement during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface microhardness of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with anti-HBs titers >= 10 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum prostate-specific antigen (PSA) decline of > or = 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of passing tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from cardiovascular causes or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Average radial deviation of seeds from planned position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risky sexual behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: knee extension moment during landing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ankle dorsiflexion during landing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: biceps femoris muscle activity during preactivation and landing phases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean time to maintain gastric pH >4 for 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first reach pH 4 after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 25-hydroxyvitamin D serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TT-specific immunoglobulin G (IgG) boost efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incident STIs
Endpoint domain: Adverse events/effects
Primary endpoint: Need for HBT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of postoperative SIRS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chest infection
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rates at 18-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to postpartum visit schedule
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sunburn incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recovery to TOF ratio 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indwelling catheter time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of wheal and flare reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in activity and drowsiness scales
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: distress and discomfort after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: well-being after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First fit success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myopia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of GERD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to return to normal serum alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to normal total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain degrees during colonoscope insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's satisfactoriness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: knowledge of psychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: LBP recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of inflammatory mediators (leucocyte, CRP, TNF‐α, IL‐6, IL‐8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival of severe pneumonia with acute kidney injury
Endpoint domain: Mortality/survival
Primary endpoint: Antibody titers of 1:40 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of hip fractures
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: children's knowledge on breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dehydroepiandrosterone sulfate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes